Aarti Drugs releases Consolidated Quarterly Results for March 31, 2023. Aarti Drugs has announced an increase in total income from Rs. 664.97 Crores as of December 31, 2022, to Rs. 743.28 Crores as of March 31, 2023. The net profit for the company has decreased from Rs. 36.67 Crores as of December 31, 2022, to Rs. 56.18 Crores as of March 31, 2023. However, the earnings per share (EPS) have improved, increasing from Rs. 3.96 on December 31, 2022, to Rs. 6.07 on March 31, 2023, according to the company’s statement.
Aarti Drugs Quarterly Results (Q4 FY2023) – Quarter-over-Quarter Comparison:
Total income of the company is Rs. 743.28 Crores (March 31, 2023) vs. Rs. 664.97 Crores (December 31, 2022)
Net profit/loss: Rs. 56.18 Crores (March 31, 2023) vs. Rs. 36.67 Crores (December 31, 2022)
EPS: Rs. 6.07 (March 31, 2023) vs. Rs. 3.96 (December 31, 2022)
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹ 743.28 Cr | ₹ 664.97 Cr | ⬆ 11.78% |
| Net Profit | ₹ 56.18 Cr | ₹ 36.67 Cr | ⬆ 53.20% |
| EPS | ₹ 6.07 | ₹ 3.96 | ⬆ 53.28% |
Aarti Drugs Quarterly Results (Q4 FY2023) – Year-over-Year Comparison:
Total income of the company is Rs. 743.28 Crores (March 31, 2023) vs. Rs. 697.23 Crores (March 31, 2022)
Net profit/loss: Rs. 56.18 Crores (March 31, 2023) vs. Rs. 55.32 Crores (March 31, 2022)
EPS: Rs. 6.07 (March 31, 2023) vs. Rs. 5.97 (March 31, 2022)
| Financials | Q3 FY2023 | Q3 FY2022 | % Change |
| Total Income | ₹ 743.28 Cr | ₹ 697.23 Cr | ⬆ 6.60% |
| Net Profit | ₹ 56.18 Cr | ₹ 55.32 Cr | ⬆ 1.55% |
| EPS | ₹ 6.07 | ₹ 5.97 | ⬆ 1.68% |
Aarti Drugs Quarterly Results (Year Ended FY2023) – Year-over-Year Comparison:
Total income of the company is Rs. 2718.25 Crores (March 31, 2023) vs. Rs. 2499.96 Crores (March 31, 2022)
Net profit/loss: Rs. 166.36 Crores (March 31, 2023) vs. Rs. 205 Crores (March 31, 2022)
EPS: Rs. 17.97 (March 31, 2023) vs. Rs. 22.12 (March 31, 2022)
| Financials | 12 Months Ended FY2023 | 12 Months Ended FY2022 | % Change |
| Total Income | ₹ 2718.25 Cr | ₹ 2499.96 Cr | ⬆ 8.73% |
| Net Profit | ₹ 166.36 Cr | ₹ 205 Cr | ⬇ -18.85% |
| EPS | ₹ 17.97 | ₹ 22.12 | ⬇ -18.76% |
Aarti Drugs Share Dividend Announcement / Record Date:
The Board of Directors has declared an Interim Dividend of ₹1 per Equity Share of Face Value of ₹10 each of the Company (10% of Face Value). Total Dividend for FY23 stood at ₹1 per Equity Share (Interim Dividend of ₹10 per Equity Share)
| Dividend | Record Date |
| ₹1 per Equity Share | Coming Soon |
The dividend’s record date has not yet come
About Aarti Drugs:
Aarti Drugs Ltd is a pharmaceutical firm that produces bulk drugs and specialty chemicals, encompassing vitamins, sedatives, and an extensive range of drugs such as anti-inflammatory, anti-asthma, anti-arthritis, anti-fungal, anti-diabetic, anti-osteoporosis, anti-cholinergic, and anti-depressant medications.
Download Full PDF Q4 Results Aarti Drugs:
For More Latest News Click Here
